FDA Approves UroGen’s Zusduri for Recurrent Low-Grade Intermediate-Risk Bladder Cancer

June 17, 2025

Top FDA Compliance Risks Facing Emerging Biotech Startups

March 24, 2026

Crescent Boosts Pipeline with Kelun Deal Worth $80M

December 4, 2025

Must Read

Top 10 AI Trends Reshaping Precision Medicine

October 11, 2026

The Economics of Rare Disease Drug Development

October 11, 2026

The Economics of Decentralized Clinical Trials

October 11, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

MimiVax’s brain cancer vaccine misses phase 2b goal, but CEO sees a path forward in younger patients

Cerevance’s Solengepras Meets Phase 3 Goal in Parkinson’s Disease Trial

Zealand’s obesity medication fails once more in phase 3

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

Theramex purchases Asieris’ innovative cervical lesion treatment for up to $250 million

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Merck anticipates a significant win for the $3 billion eye disease opportunity

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Top 10 AI Trends Reshaping Precision Medicine

The Economics of Rare Disease Drug Development

The Economics of Decentralized Clinical Trials

Top 10 Digital Biomarkers Changing Clinical Research

Commercial

Camber Pharmaceuticals to bring generic Toprol XL to the market

Editor Picks

FDA Approves UroGen’s Zusduri for Recurrent Low-Grade Intermediate-Risk Bladder Cancer

Top FDA Compliance Risks Facing Emerging Biotech Startups

Crescent Boosts Pipeline with Kelun Deal Worth $80M

Must Read

Top 10 AI Trends Reshaping Precision Medicine

The Economics of Rare Disease Drug Development

The Economics of Decentralized Clinical Trials

Hot Topics

About Us

Follow Us